NASDAQ$ZYME
Zymeworks Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
Zymeworks reported Q3 2025, revenue of $16M, net loss of $45M.
For Q3 2025, Zymeworks reported revenue of $16M, a net loss of $45M. Management discusses segment performance, capital allocation, and sector risks in the quarterly filing.
- Revenue $16M.
- Net loss $45M.
- Zymeworks MD&A covers liquidity, credit, and operating priorities.
Headline financials
Revenue & EPS history
Zymeworks · Revenue · Quarterly
$27.6M
Forward guidance
Biotech and cannabis outlook centers on trials, regulatory milestones, and cash runway.
Tailwinds
- Pipeline progress.
- Partnership optionality.
- Cost reduction programs.
Headwinds
- Trial and regulatory risk.
- Funding and dilution.
- Competitive landscape.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 13 quarterly earnings reports · overlaid with Q3 2025
-1.2%
Avg return
Earnings day
-0.4%
Avg return
5 days after
+7.6%
Avg return
30 days after
38%
5 / 13 earnings
Positive
+1.4%
Q1 2023
Best reaction
-8.0%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.6% | -13.5% | -13.0% | |
| Q4 2025 | +0.1% | +3.4% | +11.4% | |
| Q3 2025 | -8.0% | +8.2% | +49.1% | |
| Q1 2025 | -0.1% | -0.6% | +11.3% | |
| Q4 2024 | -8.0% | -11.2% | -16.9% | |
| Q3 2024 | +1.0% | +1.2% | +11.7% | |
| Q2 2024 | +0.0% | +4.3% | +22.4% | |
| Q1 2024 | +0.0% | -8.3% | -18.4% | |
| Q4 2023 | +0.0% | +1.6% | +3.8% | |
| Q3 2023 | +1.2% | +0.1% | +31.2% | |
| Q3 2021 | +0.0% | -1.3% | +10.3% | |
| Q2 2023 | +0.8% | -3.6% | -7.5% | |
| Q1 2023 | +1.4% | +14.1% | +2.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro